📊 BRNS Key Takeaways
Investment Thesis
Barinthus is a pre-revenue biopharmaceutical company in clinical development with no product sales, generating -$66.4M net losses and -$48.0M operating cash burn. Despite adequate cash reserves of $70.5M providing 12-14 months of runway at current burn rates, the company faces existential risk with zero revenue generation, deeply negative profitability metrics (ROE -89.5%, ROA -67.7%), and no demonstrated path to commercialization or profitability.
BRNS Strengths
- Strong liquidity position with $70.5M cash and 7.77x current ratio
- No long-term debt providing financial flexibility
- Adequate working capital to fund near-term operations
BRNS Risks
- Zero revenue with -100% YoY decline indicates failed commercialization or clinical programs
- Severe cash burn of -$48.0M annually will exhaust reserves within 12-14 months without capital raise
- No product portfolio generating revenue; entirely dependent on clinical trial success with high failure risk
- Negative ROE (-89.5%) and ROA (-67.7%) indicate value destruction and poor asset utilization
- No insider buying activity suggests limited management confidence in company direction
Key Metrics to Watch
- Cash balance and runway - critical indicator of survival timeline
- Clinical trial progression and regulatory milestones for pipeline candidates
- Operating cash flow trend and achievement of clinical endpoints
- Potential capital raises or financing events to extend runway
- Revenue generation from any approved or commercialized products
BRNS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.77x current ratio provides a solid financial cushion.
BRNS Profitability Ratios
BRNS vs Healthcare Sector
How Barinthus Biotherapeutics plc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BRNS Balance Sheet & Liquidity
BRNS 5-Year Financial Trend
5-Year Trend Summary: Barinthus Biotherapeutics plc.'s revenue has grown significantly by 210% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.55 indicates the company is currently unprofitable.
BRNS Growth Metrics (YoY)
BRNS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$8.1M | $-0.21 |
| Q3 2024 | N/A | -$8.1M | $-0.21 |
| Q2 2024 | N/A | -$16.9M | $-0.43 |
| Q1 2024 | N/A | -$15.5M | $-0.40 |
| Q3 2023 | $802.0K | $8.2M | $0.22 |
| Q2 2023 | $334.0K | $15.7M | $0.41 |
| Q1 2023 | $468.0K | $2.6M | $0.07 |
| Q3 2022 | $19.0K | -$4.6M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BRNS Capital Allocation
BRNS SEC Filings
Access official SEC EDGAR filings for Barinthus Biotherapeutics plc. (CIK: 0001828185)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRNS
What is the AI rating for BRNS?
Barinthus Biotherapeutics plc. (BRNS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRNS's key strengths?
Strong liquidity position with $70.5M cash and 7.77x current ratio. No long-term debt providing financial flexibility.
What are the risks of investing in BRNS?
Zero revenue with -100% YoY decline indicates failed commercialization or clinical programs. Severe cash burn of -$48.0M annually will exhaust reserves within 12-14 months without capital raise.
What is BRNS's revenue and growth?
Barinthus Biotherapeutics plc. reported revenue of $0.0.
Does BRNS pay dividends?
Barinthus Biotherapeutics plc. does not currently pay dividends.
Where can I find BRNS SEC filings?
Official SEC filings for Barinthus Biotherapeutics plc. (CIK: 0001828185) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRNS's EPS?
Barinthus Biotherapeutics plc. has a diluted EPS of $-1.64.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.